
## Kerry L Burnstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5913459/publications.pdf Version: 2024-02-01



KEDDY L RIIDNSTEIN

#	Article	IF	CITATIONS
1	Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy. Journal of Cellular Biochemistry, 2005, 95, 657-669.	2.6	106
2	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723.	1.9	105
3	The microRNA -23b/-27b Cluster Suppresses the Metastatic Phenotype of Castration-Resistant Prostate Cancer Cells. PLoS ONE, 2012, 7, e52106.	2.5	78
4	Vav3, a Rho GTPase Guanine Nucleotide Exchange Factor, Increases during Progression to Androgen Independence in Prostate Cancer Cells and Potentiates Androgen Receptor Transcriptional Activity. Molecular Endocrinology, 2006, 20, 1061-1072.	3.7	58
5	Vav3 Enhances Androgen Receptor Splice Variant Activity and Is Critical for Castration-Resistant Prostate Cancer Growth and Survival. Molecular Endocrinology, 2012, 26, 1967-1979.	3.7	49
6	Ligand-Independent Activation of Androgen Receptors by Rho GTPase Signaling in Prostate Cancer. Molecular Endocrinology, 2008, 22, 597-608.	3.7	46
7	Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1084-1089.	7.1	40
8	Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer. Nature Communications, 2017, 8, 1204.	12.8	40
9	Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 11298-11303.	7.1	38
10	Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. Science Translational Medicine, 2019, 11, .	12.4	36
11	Identification of an oncogenic network with prognostic and therapeutic value in prostate cancer. Molecular Systems Biology, 2018, 14, e8202.	7.2	33
12	VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Research, 2014, 16, R53.	5.0	28
13	Targeting IGF-IR with Ganitumab Inhibits Tumorigenesis and Increases Durability of Response to Androgen-Deprivation Therapy in VCaP Prostate Cancer Xenografts. Molecular Cancer Therapeutics, 2013, 12, 394-404.	4.1	25
14	Targeting AR Variant–Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities. Molecular Cancer Research, 2017, 15, 1469-1480.	3.4	21
15	Novel Interaction between the Co-chaperone Cdc37 and Rho GTPase Exchange Factor Vav3 Promotes Androgen Receptor Activity and Prostate Cancer Growth*. Journal of Biological Chemistry, 2013, 288, 5463-5474.	3.4	20
16	Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis. Oncogene, 2019, 38, 838-851.	5.9	19
17	Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity. Molecular Cancer Therapeutics, 2016, 15, 1353-1363.	4.1	15
18	Essential Components of Cancer Education. Cancer Research, 2015, 75, 5202-5205.	0.9	10

Kerry L Burnstein

#	Article	IF	CITATIONS
19	The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor. Oncogene, 2022, 41, 2824-2832.	5.9	10
20	A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells. Oncotarget, 2014, 5, 9007-9021.	1.8	6
21	Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin Signaling Axis by Repurposing Vaptans. Molecular Cancer Research, 2022, 20, 1295-1304.	3.4	3
22	Signaling Mechanisms of Vav3, a Guanine Nucleotide Exchange Factor and Androgen Receptor Coactivator, in Physiology and Prostate Cancer Progression. , 2013, , 187-205.		0
23	Preclinical efficacy of growth hormone-releasing hormone antagonist MIA-602 for androgen-dependent and castration-resistant human prostate cancer Journal of Clinical Oncology, 2014, 32, 221-221.	1.6	0